Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Mortality
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Nigella Sativa  COVID-19 treatment studies for Nigella Sativa  C19 studies: Nigella Sativa  Nigella Sativa   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 nigella sativa studies
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies 67% 4 1,291 Improvement, Studies, Patients Relative Risk, 95% CI Mortality 87% 2 732 Hospitalization 75% 1 183 Recovery 69% 2 393 Viral clearance 82% 1 210 RCTs 84% 3 915 Peer-reviewed 69% 3 978 Prophylaxis 62% 1 376 Early 84% 3 915 Nigella Sativa for COVID-19 c19ns.com Dec 7, 2021 Favors nigella sativa Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ashraf (RCT) 82% 0.18 [0.04-0.80] death 2/157 11/156 CT​1 Improvement, RR [CI] Treatment Control Al-Haidari (RCT) 96% 0.04 [0.00-0.70] death 0/160 14/259 Koshak (RCT) 75% 0.25 [0.03-2.22] hosp. 1/91 4/92 Tau​2 = 0.00; I​2 = 0.0% Early treatment 84% 0.16 [0.05-0.48] 3/408 29/507 84% improvement Al-Haidari 62% 0.38 [0.31-0.46] symp. case 68/188 180/188 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 62% 0.38 [0.31-0.46] 68/188 180/188 62% improvement All studies 67% 0.33 [0.21-0.52] 71/596 209/695 67% improvement 4 nigella sativa COVID-19 studies c19ns.com Dec 7, 2021 1 CT: study uses combined treatmentTau​2 = 0.06; I​2 = 10.1%; Z = 4.72 Effect extraction pre-specified Favors nigella sativa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ashraf (RCT) 82% 0.18 [0.04-0.80] 2/157 11/156 CT​1 Improvement, RR [CI] Treatment Control Al-Haidari (RCT) 96% 0.04 [0.00-0.70] 0/160 14/259 Tau​2 = 0.00; I​2 = 0.0% Early treatment 87% 0.13 [0.04-0.49] 2/317 25/415 87% improvement All studies 87% 0.13 [0.04-0.49] 2/317 25/415 87% improvement 2 nigella sativa COVID-19 mortality results c19ns.com Dec 7, 2021 1 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 3.02 Favors nigella sativa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Koshak (RCT) 75% 0.25 [0.03-2.22] hosp. 1/91 4/92 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 75% 0.25 [0.03-2.22] 1/91 4/92 75% improvement All studies 75% 0.25 [0.03-2.22] 1/91 4/92 75% improvement 1 nigella sativa COVID-19 hospitalization result c19ns.com Dec 7, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 1.24 Favors nigella sativa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ashraf (RCT) 82% 0.18 [0.04-0.80] death 2/157 11/156 CT​1 Improvement, RR [CI] Treatment Control Al-Haidari (RCT) 96% 0.04 [0.00-0.70] death 0/160 14/259 Koshak (RCT) 75% 0.25 [0.03-2.22] hosp. 1/91 4/92 Tau​2 = 0.00; I​2 = 0.0% Early treatment 84% 0.16 [0.05-0.48] 3/408 29/507 84% improvement All studies 84% 0.16 [0.05-0.48] 3/408 29/507 84% improvement 3 nigella sativa COVID-19 serious outcomes c19ns.com Dec 7, 2021 1 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 3.23 Effect extraction pre-specified Favors nigella sativa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ashraf (RCT) 84% 0.16 [0.11-0.24] no recov. 107 (n) 103 (n) CT​1 Improvement, RR [CI] Treatment Control Koshak (RCT) 43% 0.57 [0.42-0.78] no recov. 34/91 60/92 Tau​2 = 0.76; I​2 = 96.2% Early treatment 69% 0.31 [0.09-1.05] 34/198 60/195 69% improvement All studies 69% 0.31 [0.09-1.05] 34/198 60/195 69% improvement 2 nigella sativa COVID-19 recovery results c19ns.com Dec 7, 2021 1 CT: study uses combined treatmentTau​2 = 0.76; I​2 = 96.2%; Z = 1.88 Favors nigella sativa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ashraf (RCT) 82% 0.18 [0.12-0.27] viral+ 107 (n) 103 (n) CT​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 82% 0.18 [0.12-0.27] 0/107 0/103 82% improvement All studies 82% 0.18 [0.12-0.27] 0/107 0/103 82% improvement 1 nigella sativa COVID-19 viral clearance result c19ns.com Dec 7, 2021 1 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 8.68 Favors nigella sativa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ashraf (RCT) 82% 0.18 [0.04-0.80] death 2/157 11/156 CT​1 Improvement, RR [CI] Treatment Control Al-Haidari (RCT) 96% 0.04 [0.00-0.70] death 0/160 14/259 Koshak (RCT) 75% 0.25 [0.03-2.22] hosp. 1/91 4/92 Tau​2 = 0.00; I​2 = 0.0% Early treatment 84% 0.16 [0.05-0.48] 3/408 29/507 84% improvement All studies 84% 0.16 [0.05-0.48] 3/408 29/507 84% improvement 3 nigella sativa COVID-19 Randomized Controlled Trials c19ns.com Dec 7, 2021 1 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 3.23 Effect extraction pre-specified Favors nigella sativa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ashraf (RCT) 82% 0.18 [0.04-0.80] 2/157 11/156 CT​1 Improvement, RR [CI] Treatment Control Al-Haidari (RCT) 96% 0.04 [0.00-0.70] 0/160 14/259 Tau​2 = 0.00; I​2 = 0.0% Early treatment 87% 0.13 [0.04-0.49] 2/317 25/415 87% improvement All studies 87% 0.13 [0.04-0.49] 2/317 25/415 87% improvement 2 nigella sativa COVID-19 RCT mortality results c19ns.com Dec 7, 2021 1 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 3.02 Favors nigella sativa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Al-Haidari (RCT) 96% 0.04 [0.00-0.70] death 0/160 14/259 Improvement, RR [CI] Treatment Control Koshak (RCT) 75% 0.25 [0.03-2.22] hosp. 1/91 4/92 Tau​2 = 0.00; I​2 = 0.0% Early treatment 87% 0.13 [0.02-0.72] 1/251 18/351 87% improvement Al-Haidari 62% 0.38 [0.31-0.46] symp. case 68/188 180/188 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Prophylaxis 62% 0.38 [0.31-0.46] 68/188 180/188 62% improvement All studies 69% 0.31 [0.15-0.67] 69/439 198/539 69% improvement 3 nigella sativa COVID-19 peer reviewed trials c19ns.com Dec 7, 2021 Tau​2 = 0.17; I​2 = 18.1%; Z = 3.01 Effect extraction pre-specified Favors nigella sativa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ashraf (RCT) 82% 0.18 [0.04-0.80] death 2/157 11/156 CT​1 Improvement, RR [CI] Treatment Control Ashraf (RCT) 67% 0.33 [0.01-7.99] death 0/107 1/103 CT​1 Ashraf (RCT) 79% 0.21 [0.05-0.92] death 2/50 10/53 CT​1 Ashraf (RCT) 84% 0.16 [0.11-0.24] no recov. 107 (n) 103 (n) CT​1 Ashraf (RCT) 75% 0.25 [0.15-0.41] no recov. 50 (n) 53 (n) CT​1 Ashraf (RCT) 82% 0.18 [0.12-0.27] viral+ 107 (n) 103 (n) CT​1 Ashraf (RCT) 77% 0.23 [0.14-0.38] viral+ 50 (n) 53 (n) CT​1 Al-Haidari (RCT) 96% 0.04 [0.00-0.70] death 0/160 14/259 Al-Haidari (RCT) 93% 0.07 [0.02-0.30] severe case 2/160 44/259 Koshak (RCT) 75% 0.25 [0.03-2.22] hosp. 1/91 4/92 Koshak (RCT) 43% 0.57 [0.42-0.78] no recov. 34/91 60/92 Al-Haidari 62% 0.38 [0.31-0.46] symp. case 68/188 180/188 nigella sativa COVID-19 outcomes c19ns.com Dec 7, 2021 Favors nigella sativa Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit